CD274 and triple-negative breast carcinoma: In a large phase III trial in patients with triple-negative breast cancer, a combination of atezolizumab (a fully humanized IgG1 against PD-L1) with nab-paclitaxel was shown to result in PFS of 7.2 months compared to 5.5 months for placebo plus nab-paclitaxel (p = 0.002) [33].